Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Kala Pharmaceuticals (KALA) Tops Q1 EPS by 19c, Revenues Miss
May 5, 2021 7:23 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q1 EPS of ($0.49), $0.19 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $3.27 million versus the consensus estimate of $4.18 million.
We are early in the launch of EYSUVIS and encouraged by our progress... More
